Raymond T Bartus
Overview
Explore the profile of Raymond T Bartus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2617
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Herzog C, Bishop K, Brown L, Wilson A, Kordower J, Bartus R
Drug Deliv Transl Res
. 2015 Mar;
1(5):361-82.
PMID: 25788422
Efforts to develop neurotrophic factors to restore function and protect dying neurons in chronic neurodegenerative diseases like Alzheimer's (AD) and Parkinson's (PD) have been attempted for decades. Despite abundant data...
12.
Rafii M, Baumann T, Bakay R, Ostrove J, Siffert J, Fleisher A, et al.
Alzheimers Dement
. 2014 Jan;
10(5):571-81.
PMID: 24411134
Background: Nerve growth factor (NGF) is an endogenous neurotrophic-factor protein with the potential to restore function and to protect degenerating cholinergic neurons in Alzheimer's disease (AD), but safe and effective...
13.
Bartus R, Weinberg M, Samulski R
Mol Ther
. 2013 Dec;
22(3):487-497.
PMID: 24356252
Over the past decade, nine gene therapy clinical trials for Parkinson's disease (PD) have been initiated and completed. Starting with considerable optimism at the initiation of each trial, none of...
14.
Kordower J, Olanow C, Dodiya H, Chu Y, Beach T, Adler C, et al.
Brain
. 2013 Jul;
136(Pt 8):2419-31.
PMID: 23884810
The pace of nigrostriatal degeneration, both with regards to striatal denervation and loss of melanin and tyrosine hydroxylase-positive neurons, is poorly understood especially early in the Parkinson's disease process. This...
15.
Herzog C, Brown L, Kruegel B, Wilson A, Tansey M, Gage F, et al.
Neurobiol Dis
. 2013 May;
58:38-48.
PMID: 23631873
This paper reassesses the currently accepted viewpoint that targeting the terminal fields (i.e. striatum) of degenerating nigrostriatal dopamine neurons with neurotrophic factors in Parkinson's disease (PD) is sufficient for achieving...
16.
Bartus R, Baumann T, Siffert J, Herzog C, Alterman R, Boulis N, et al.
Neurology
. 2013 Apr;
80(18):1698-701.
PMID: 23576625
Objective: In an effort to account for deficiencies in axonal transport that limit the effectiveness of neurotrophic factors, this study tested the safety and feasibility, in moderately advanced Parkinson disease...
17.
Bartus R, Baumann T, Brown L, Kruegel B, Ostrove J, Herzog C
Neurobiol Aging
. 2012 Aug;
34(1):35-61.
PMID: 22926166
Neurotrophic factors have long shown promise as potential therapies for age-related neurodegenerative diseases. However, 20 years of largely disappointing clinical results have underscored the difficulties involved with safely and effectively...
18.
Bartus R
Neurobiol Dis
. 2012 Apr;
48(2):153-78.
PMID: 22525569
While the therapeutic potential of neurotrophic factors has been well-recognized for over two decades, attempts to translate that potential to the clinic have been disappointing, largely due to significant delivery...
19.
Anton R, Litten R, Falk D, Palumbo J, Bartus R, Robinson R, et al.
Neuropsychopharmacology
. 2011 Sep;
37(2):402-11.
PMID: 21900883
Although progress has been made in the treatment of alcohol use disorders, more effective treatments are needed. In the last 15 years, several medications have been approved for use in...
20.
Bartus R, Brown L, Wilson A, Kruegel B, Siffert J, Johnson Jr E, et al.
Neurobiol Dis
. 2011 Jun;
44(1):38-52.
PMID: 21704161
Recent analyses of autopsied brains from subjects previously administered AAV2-neurturin (NRTN) gene transfer argues that optimizing the effects of neurotrophic factors in Parkinson's disease (PD) likely requires delivery to both...